Adagene Inc. ADAG
We take great care to ensure that the data presented and summarized in this overview for Adagene Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADAG
View all-
Wu Xi App Tec Co., Ltd. Shanghai, F43.98MShares$7.49 Million46.44% of portfolio
-
Fil LTD Hamilton, D03.6MShares$6.77 Million0.01% of portfolio
-
Sc China Holding LTD N/A, K31.34MShares$2.53 Million0.11% of portfolio
-
General Atlantic LLC New York, NY264KShares$496,3200.02% of portfolio
-
Exome Asset Management LLC New York, NY263KShares$493,7350.4% of portfolio
-
Barclays PLC London, X0187KShares$351,3770.0% of portfolio
-
Morgan Stanley New York, NY96.1KShares$180,6130.0% of portfolio
-
Mill Creek Capital Advisors, LLC Conshohocken, PA90.9KShares$170,9070.0% of portfolio
-
Catalina Capital Group, LLC Torrance, CA12.7KShares$23,9450.01% of portfolio
-
Geode Capital Management, LLC Boston, MA10.3KShares$19,3800.0% of portfolio
Latest Institutional Activity in ADAG
Top Purchases
Top Sells
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Insider Transactions at ADAG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|